Biotechnology

Tradr 2X Long SNPS Daily ETF

Lightmatter Partners with Synopsys to Optimize AI Infrastructure

Synaptogenix Renamed as TAO Synergies to Focus on Cryptocurrency and AI Integration

Synaptogenix Acquires TAO for Cryptocurrency Treasury Strategy

Synaptogenix's First Acquisition of TAO and Yield Generation through Staking

Synaptogenix Inc Launches TAO Token Acquisition Strategy

Synaptogenix released FY2025 Q1 earnings on May 15 (EST) with actual revenue of USD 0 and EPS of USD 0.04

Synaptogenix released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.1667 USD (forecast -2.06 USD)

Synaptogenix released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -10.99 USD (forecast -7.48 USD)

Synaptogenix released FY2024 Q3 earnings on November 12, 2024 (EST), with actual EPS -4.5823 (forecast -1.95)

Synaptogenix released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of 0 and EPS of -6.1768

Synaptogenix: Maxim Group upgrades from Hold to Buy

Synaptogenix announces FDA approval of IND application for the use of Bryostatin-1 in clinical trials for multiple sclerosis

Synaptogenix released FY2023 annual earnings on April 1, 2024 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -29.5629 USD (forecast -39.5 USD)

Synaptogenix released FY2023 Q4 earnings on April 1 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.4513 USD (forecast -9.5 USD)

Synaptogenix released FY2023 cumulative Q3 earnings on November 14, 2023 (EST), with net income -12.55M USD and EPS -42.1054

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SNPS

SNPX

Synopsys (NASDAQ:SNPS) is currently priced below $500, but analysts suggest it may not fully support the AI narrative driving its valuation. Despite a strong Q1 FY2026 revenue of $2.41B (+66% YoY) and a $11.3B backlog, its Design IP revenue fell 6% YoY. The stock trades at a high P/E ratio of 77x, raising concerns about its pricing relative to competitors with clearer AI exposure. Investors are advised to wait for the upcoming May 27 report to assess growth potential and market conditions.

Synopsys

NVIDIA

Alphabet

Alphabet - C

Amazon

NVIDIA Corporation

Buy, sell or hold synopsis below $500?

SOXX

SOXL

Synopsys reported Q1 FY26 results exceeding expectations, driven by the Ansys acquisition and AI chip design demand. The Ansys deal has expanded Synopsys' market significantly, enhancing its role in complex engineering. While the integration shows promise, risks remain regarding execution and cost pressures. Analysts project Synopsys' revenue at $12.1 billion and earnings at $1.8 billion by 2029, with a fair value estimate between $473.17 and $535.42, indicating potential upside.

Simplywall

SPDR S&P Software

SPDR S&P Semicon

iShares Expanded Tech Software Sector ETF

iShares Semiconductor ETF

VanEck Semiconductor ETF

Direxion Semicon Bull 3X

Invesco Semiconductors ETF

ISHRS S&P Glb It

ANSYS

Taiwan Semiconductor

Stronger‑Than‑Expected Ansys Integration Could Be A Game Changer For Synopsys (SNPS)

ARMW

ARMU

AMI has launched a 'Shift Left' initiative in collaboration with Arm and Synopsys to enhance the Arm Total Design process. This initiative allows for earlier verification of firmware, reducing design costs and time-to-market while mitigating risks. By integrating AMI OnSil and Aptio V firmware validation into the RTL stage, the initiative aims to deliver high-quality silicon faster, addressing the growing demand for specialized compute solutions.

- AMI has announced an accelerated "Shift Left" initiative in collaboration with Arm and Synopsys to enhance the ASIC design flow.  
- This initiative allows verification of AMI firmware earlier in the process, significantly lowering design costs, reducing time-to-market, and mitigating risks.  
- By integrating pre-silicon firmware validation into the RTL stage, the initiative supports the Arm Total Design ecosystem, enabling faster, higher-quality silicon production.

prnewswire

Roundhill ARM WeeklyPay ETF

T-Rex 2X Long ARM Daily Target ETF

11:34 ETAMI Announces a Shift-Left Initiative to De-Risk SoC Development for Arm Total Design in Collaboration with Arm and Synopsys

Synopsys (SNPS) shares closed at $502.42, reflecting a 14.6% gain over the past month. Despite a slight negative return over the past year, the stock is considered modestly undervalued at 6% below its fair value of $534.65. The integration of Ansys is expected to enhance growth in engineering solutions across various sectors. However, high P/E ratios indicate potential valuation risks. Investors are advised to weigh opportunities against risks, including export restrictions and integration challenges.

A Look At Synopsys (SNPS) Valuation After Recent Share Price Momentum And Ansys Integration Prospects

Synopsys Inc. (SNPS) shares fell 1.49% to $502.42 on Friday, underperforming against competitors amid a declining stock market. The S&P 500 dropped 1.24%, while Synopsys closed 22.91% below its 52-week high of $651.73. Competitors had mixed results: Applied Materials fell 0.89%, Lam Research dropped 4.82%, and Autodesk rose 1.18%. Trading volume was 1.4 million, below the 50-day average of 1.7 million.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Applied Materials

Lam Research

Autodesk

Synopsys Inc. Stock Underperforms Friday When Compared To Competitors

The article discusses three profitable AI stocks: Cosmo, Synopsys, and SCREEN Holdings. Cosmo, a Dublin-based life sciences company, focuses on AI-assisted medical devices and has shown a shift from operating loss to profit, with no debt. Synopsys provides essential design software for chipmakers, facing challenges like high P/E ratios and export controls. SCREEN Holdings manufactures semiconductor production equipment and is expected to grow faster than the Japanese market, but faces risks from competition and reliance on China. Each company presents unique opportunities and risks for investors in the AI sector.

SCREEN Holdings Co., Ltd

Profitable AI Stocks One Debt Free Earner One Quiet Chip Powerhouse

UNIVEST FINANCIAL Corp reduced its stake in Synopsys, Inc. by 23.7% in Q4, selling 4,586 shares, leaving it with 14,725 shares valued at $6.92 million. Other institutional investors also adjusted their positions, with notable increases from Plato Investment Management and LRI Investments. Synopsys shares opened at $516.48, with a market cap of $98.94 billion. The company reported strong earnings, beating estimates, and has set FY 2026 guidance for EPS between 14.380-14.460. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $531.00.

Market Beat

Univest Financial

Keysight Tech

Morgan Stanley

HSBC Holdings Plc

HSBC

Goldman Sachs

Wells Fargo

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

HSBC 5xShortSG241213

HSBC HOLDINGS

GS Hldg R

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

UNIVEST FINANCIAL Corp Sells 4,586 Shares of Synopsys, Inc. $SNPS

Shares of Synopsys Inc. (SNPS) rose 2.23% to $516.48 on Friday, marking its seventh consecutive day of gains. Despite this increase, the stock underperformed compared to competitors like Applied Materials Inc. (AMAT), which rose 6.04%, and Lam Research Corp. (LRCX), which rose 2.63%. Synopsys remains 20.75% below its 52-week high of $651.73 reached on July 30. The overall market was positive, with the S&P 500 up 0.84%.

Synopsys Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Synopsys (SNPS) has seen a significant share price increase of 27% in the past month and 23% over three months, with a current trading price around $504. Analysts suggest a fair value of $535, indicating the stock is modestly undervalued. However, its P/E ratio of 87x is substantially higher than the industry average of 29.3x, raising concerns about future growth expectations. Investors should consider the balance of optimism and risks, including geopolitical factors and integration challenges with Ansys.

A Look At Synopsys (SNPS) Valuation After Recent Share Price Momentum

Tradr 2X Long SNPS Daily ETF(SNPX.US)

Buy, sell or hold synopsis below $500?

Stronger‑Than‑Expected Ansys Integration Could Be A Game Changer For Synopsys (SNPS)

11:34 ETAMI Announces a Shift-Left Initiative to De-Risk SoC Development for Arm Total Design in Collaboration with Arm and Synopsys

A Look At Synopsys (SNPS) Valuation After Recent Share Price Momentum And Ansys Integration Prospects

Synopsys Inc. Stock Underperforms Friday When Compared To Competitors